Replicating human diabetes: insights from a novel animal model

Area of Science:

• Endocrinology and Metabolism
• Preclinical Research Models
• Diabetes Pathophysiology

Background:

• Type 2 diabetes is a global pandemic with complex, multifactorial pathogenesis.
• Current animal models inadequately replicate type 2 diabetes pathophysiology and associated organ damage.
• Understanding beta-cell dysfunction is critical for diabetes prevention and treatment, yet remains unclear.

Purpose of the Study:

• To develop a novel, non-genotypic preclinical model for type 2 diabetes.
• To investigate the effects of combining obesity and tacrolimus (TAC) treatment on diabetes development.
• To provide a more appropriate model for studying diabetes pathophysiology and organ damage.

Main Methods:

• Sprague-Dawley male rats were fed a high-fat (HF) diet to induce obesity and metabolic syndrome.
• Tacrolimus (TAC), an immunosuppressor, was administered for 6-9 months to induce chronic hyperglycemia.
• Evaluated pancreatic changes including islet morphology, cell composition, insulin/glucagon content, and key transcription factor expression.

Main Results:

• Obese rats treated with TAC developed chronic hyperglycemia and impaired glucose tolerance.
• Significant decrease in Langerhans islet area and number, with evidence of islet fibrosis.
• Reduced insulin content, altered alpha/beta cell ratio, and decreased expression of MAFA, FOXO1A, PDX-1, and NEUROD1.

Conclusions:

• This HF diet and TAC-induced model offers a more relevant preclinical representation of type 2 diabetes.
• The model demonstrates key pathological features including hyperglycemia, islet dysfunction, and fibrosis.
• It provides a valuable tool for investigating diabetes pathogenesis and therapeutic interventions.